{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T02:22:43Z","timestamp":1775182963936,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009448","name":"Universit\u00e0 degli Studi della Campania Luigi Vanvitelli","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009448","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p><jats:bold>C<\/jats:bold>ladribine is an oral immune reconstitution therapy for relapsing multiple sclerosis (RMS). Hormonal and immune changes are responsible for the decline of disease activity in the third trimester of pregnancy and disease reactivation in the early post-partum period.We investigate the impact of pregnancy on disease activity in women with MS who conceived after cladribine treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We recruited women of childbearing age with relapsing\u2013remitting MS (RRMS) who became pregnant or not after being treated with cladribine. For both groups, demographic, clinical and radiological data were collected 1\u00a0year before and after treatment during a mean follow-up of 3.53\u00a0years. We compared disease activity over time between groups using variance analysis for repeated measures.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>48 childbearing women were included. 25 women had a pregnancy after a mean of 1.75\u00a0years from the first treatment cycle. Women with or without pregnancy did not differ in demographics or pre-cladribine disease activity. No significant differences in disease activity or EDSS worsening were found between women with or without pregnancy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Our findings suggest that pregnancy does not appear to influence disease activity and disability in women previously treated with cladribine; further studies with larger numbers and longer follow-up are needed to confirm this finding.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-024-12291-7","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T05:01:56Z","timestamp":1712120516000},"page":"4039-4045","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pregnancy effect on disease activity in women with multiple sclerosis treated with cladribine"],"prefix":"10.1007","volume":"271","author":[{"given":"E.","family":"Signoriello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Foschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Lanzillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Frau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Cocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Borriello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ianniello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Trotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Landi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. T.","family":"Maniscalco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Ruscica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Toscano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Patti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Zangh\u00ec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Fantozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Centonze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Lus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8561-9720","authenticated-orcid":false,"given":"S.","family":"Bonavita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,3]]},"reference":[{"issue":"1","key":"12291_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.13819","volume":"26","author":"R Dobson","year":"2019","unstructured":"Dobson R, Giovannoni G (2019) Multiple sclerosis - a review. Eur J Neurol 26(1):27\u201340","journal-title":"Eur J Neurol"},{"key":"12291_CR2","doi-asserted-by":"publisher","first-page":"100889","DOI":"10.1016\/j.yfrne.2020.100889","volume":"60","author":"M Sparaco","year":"2021","unstructured":"Sparaco M, Bonavita S (2021) The role of sex hormones in women with multiple sclerosis: from puberty to assisted reproductive techniques. Front Neuroendocrinol 60:100889","journal-title":"Front Neuroendocrinol"},{"issue":"9","key":"12291_CR3","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1177\/1352458519830588","volume":"25","author":"E Portaccio","year":"2019","unstructured":"Portaccio E, Amato MP (2019) Breastfeeding and post-partum relapses in multiple sclerosis patients. Mult Scler 25(9):1211\u20131216","journal-title":"Mult Scler"},{"issue":"3","key":"12291_CR4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40263-015-0238-y","volume":"29","author":"MP Amato","year":"2015","unstructured":"Amato MP, Portaccio E (2015) Fertility, pregnancy, and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs. CNS Drugs 29(3):207\u2013220","journal-title":"CNS Drugs"},{"issue":"10","key":"12291_CR5","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s40262-017-0516-6","volume":"56","author":"RM Savic","year":"2017","unstructured":"Savic RM, Novakovic AM, Ekblom M, Munafo A, Karlsson MO (2017) Population pharmacokinetics of cladribine in patients with multiple sclerosis. Clin Pharmacokinet 56(10):1245\u20131253","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"12291_CR6","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1177\/1352458517727603","volume":"24","author":"G Giovannoni","year":"2018","unstructured":"Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, Dangond F, Adeniji AK, Vermersch P (2018) Safety and efficacy of cladribine tablets in patients with relapsing remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Mult Scler 24(12):1594\u20131604","journal-title":"Mult Scler"},{"issue":"7","key":"12291_CR7","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40264-020-00948-x","volume":"43","author":"G Giovannoni","year":"2020","unstructured":"Giovannoni G (2020) Pregnancy outcomes during the clinical development program of cladribine in multiple sclerosis: an integrated analysis of safety. Drug Saf 43(7):635\u2013643","journal-title":"Drug Saf"},{"issue":"2","key":"12291_CR8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00415-009-5359-0","volume":"257","author":"HP Hartung","year":"2010","unstructured":"Hartung HP, Aktas O, Kieseier B, Giancarlo Comi GC (2010) Development of oral cladribine for the treatment of multiple sclerosis. J Neurol 257(2):163\u2013170","journal-title":"J Neurol"},{"issue":"9","key":"12291_CR9","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1093\/brain\/awac016","volume":"145","author":"FD Lublin","year":"2022","unstructured":"Lublin FD, H\u00e4ring DA, Ganjgahi H, Ocampo A, Hatami F, \u010cuklina J, Aarden P, Dahlke F, Arnold DL, Wiendl H, Chitnis T, Nichols TE, Kieseier BC, Bermel RA (2022) How patients with multiple sclerosis acquire disability. Brain 145(9):3147\u20133161","journal-title":"Brain"},{"issue":"16","key":"12291_CR10","doi-asserted-by":"publisher","first-page":"175628642311832","DOI":"10.1177\/17562864231183221","volume":"8","author":"D Centonze","year":"2023","unstructured":"Centonze D, Amato MP, Brescia Morra V, Cocco E, De Stefano N, Gasperini C, Gallo P, Pozzilli C, Trojano M, Filippi M (2023) Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4. Ther Adv Neurol Disord 8(16):17562864231183220","journal-title":"Ther Adv Neurol Disord"},{"key":"12291_CR11","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1177\/13524585211049392","volume":"28","author":"G Giovannoni","year":"2022","unstructured":"Giovannoni G, Singer BA, Issard D et al (2022) Durabilityof no evidence of disease activity-3 (NEDA-3) inpatients receiving cladribine tablets: the CLARITYextension study. Mult Scler 28:1219\u20131228","journal-title":"Mult Scler"},{"issue":"3","key":"12291_CR12","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s40120-022-00364-6","volume":"11","author":"M Petracca","year":"2022","unstructured":"Petracca M, Ruggieri S, Barbuti E, Ianniello A, Fantozzi R, Maniscalco GT, Andreone V, Landi D, Marfia GA, Di Gregorio M, Iodice R, Sinisi L, Maida E, Missione R, Coppola C, Bonavita S, Borriello G, Centonze D, Lus G, Pozzilli C, Signoriello E (2022) Predictors of cladribine effectiveness and safety in multiple sclerosis: a real-world, multicenter, 2-year follow-up study. Neurol Ther 11(3):1193\u20131208","journal-title":"Neurol Ther"},{"issue":"7","key":"12291_CR13","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1007\/s00415-023-11700-7","volume":"270","author":"C Zanetta","year":"2023","unstructured":"Zanetta C, Rocca MA, Meani A, Martinelli V, Ferr\u00e8 L, Moiola L, Filippi M (2023) Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study. J Neurol 270(7):3553\u20133564","journal-title":"J Neurol"},{"key":"12291_CR14","doi-asserted-by":"publisher","first-page":"104459","DOI":"10.1016\/j.msard.2022.104459","volume":"69","author":"C Oreja-Guevara","year":"2023","unstructured":"Oreja-Guevara C, Brownlee W, Celius EG, Centonze D, Giovannoni G, Hodgkinson S, Kleinschnitz C, Havrdova EK, Magyari M, Selchen D, Vermersch P, Wiendl H, Van Wijmeersch B, Salloukh H, Yamout B (2023) Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: systematic literature review of real-world evidences. Mult Scler Relat Disord 69:104459","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"12291_CR15","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1177\/13524585221131486","volume":"29","author":"K Dost-Kovalsky","year":"2023","unstructured":"Dost-Kovalsky K, Thiel S, Ciplea AI, Gold R, Hellwig K (2023) Cladribine and pregnancy in women with multiple sclerosis: the first cohort study. Mult Scler 29(3):461\u2013465","journal-title":"Mult Scler"},{"issue":"12","key":"12291_CR16","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1136\/jnnp-2018-318468","volume":"89","author":"D Landi","year":"2018","unstructured":"Landi D, Ragonese P, Prosperini L, Nociti V, Haggiag S, Cortese A, Fantozzi R, Pontecorvo S, Ferraro E, Buscarinu MC, Mataluni G, Monteleone F, Salvetti M, Di Battista G, Francia A, Millefiorini E, Gasperini C, Mirabella M, Salemi G, Boffa L, Pozzilli C, Centonze D, Marfia GA (2018) Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 89(12):1272\u20131278","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"12291_CR17","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40264-020-00948-x","volume":"43","author":"G Giovannoni","year":"2020","unstructured":"Giovannoni G, Galazka A, Schick R, Leist T, Comi G, Montalban X, Damian D, Dangond F, Cook S (2020) Pregnancy outcomes during the clinical development program of cladribine in multiple sclerosis: an integrated analysis of safety. Drug Saf 43(7):635\u2013643","journal-title":"Drug Saf"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12291-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12291-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12291-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T10:24:33Z","timestamp":1720520673000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12291-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,3]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["12291"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12291-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,3]]},"assertion":[{"value":"18 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the\u00a0authors\u00a0participated in drafting the article and revising it critically for important intellectual content; E.S and S.B contributed to conception, design, analysis and\/or interpretation of the data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was approved by the local ethics committees and all participants signed an informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}